ALK Biomarkers
News and reporting on ALK biomarkers.
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
Xcovery's Ensartinib Approved for First-Line ALK-Positive NSCLC in China
The drug was previously approved in the country as a second-line treatment for ALK-positive non-small cell lung cancer patients.
Pfizer's Lorviqua Approved in EU for First-Line Treatment of ALK-Positive Advanced Lung Cancer
The drug was previously approved in Europe for second- and third-line treatment for ALK-positive advanced NSCLC.
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
Drugmakers Trying Out Decentralized Clinical Trials in Precision Oncology Though Risks Remain
Premium
The pandemic increased interest in virtual, tech-enabled enrollment strategies, but pharma wants to see if early studies succeed before jumping in.